Back to search

Peptide record

TPDB08965

PG1 Antibacterial Anticancer Antifungal Antiparasitic Antiviral Cell-penetrating Peptides Hemolysis Toxicity standard
18 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB08965
PG1
Antibacterial Anticancer Antifungal Antiparasitic Antiviral Cell-penetrating Peptides Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides Delivery and barrier-penetrating peptides
AntiBP3 dbAMP DRAMP pep-lab Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF Antifungipept CAFPdb i2APP AI4AVP dbAMP 3.0 CPPsite3.0 MLCPP 2.0 PerseuCPP APD_complete HemoPI Hemolytic2 PD_Hemolysis ToxinPred 3.0
standard
No
A 18-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
RGGRLCYCRRRFCVCVGR
Physicochemical Analysis
C88H150N36O20S4
ANDEQHIKMPSTW
R
2160.63
10.92
6
0
5
+6
1.44
-0.250
53.89
Mammalian: 1 hour Yeast: 2 min E.coli: 2 min
1740
80.53
5
Residue Composition
number
0
A
6
R
0
N
0
D
4
C
0
E
0
Q
3
G
0
H
0
I
1
L
0
K
0
M
1
F
0
P
0
S
0
T
0
W
1
Y
2
V
Amino Acid Distribution
A: 0 R: 6 N: 0 D: 0 C: 4 E: 0 Q: 0 G: 3 H: 0 I: 0 L: 1 K: 0 M: 0 F: 1 P: 0 S: 0 T: 0 W: 0 Y: 1 V: 2
Chemical Descriptors
18
C88H150N36O20S4
2160.63
10.92
+6
1.44
-0.250
Free
L
Cationic
Linear
Free
NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCCN=C)C(=O)O
Evidence Records 41 records
Evidence 1 Activity

Activity

MIC
Antibacterial
0.12 µg/mL

Target

Escherichia coli 004

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
Activity against E. coli 004(MIC 0.12 ug/ml), VREF 032 (MIC 0.25 ug/ml), P. aeruginosa ATCC 9027 (MIC 0.5 ug/ml), S. aureus ATCC 33591
Evidence 2 Activity

Activity

MIC
Antibacterial
0.5 µg/mL

Target

Pseudomonas aeruginosa ATCC 9027

Source & Reference

dbAMP DRAMP

Other

Activity against E. coli 004(MIC 0.12 ug/ml), VREF 032 (MIC 0.25 ug/ml), P. aeruginosa ATCC 9027 (MIC 0.5 ug/ml), S. aureus ATCC 33591 or MRSA (MIC 2 ug/ml) and C. albicans ATCC 10231 (MIC 8 ug/ml). It
Evidence 3 Activity

Activity

MIC
Antibacterial
2 µg/mL

Target

Staphylococcus aureus ATCC 33591 or MRSA

Source & Reference

dbAMP DRAMP

Other

004(MIC 0.12 ug/ml), VREF 032 (MIC 0.25 ug/ml), P. aeruginosa ATCC 9027 (MIC 0.5 ug/ml), S. aureus ATCC 33591 or MRSA (MIC 2 ug/ml) and C. albicans ATCC 10231 (MIC 8 ug/ml). It also inhibit B. anthracis (MIC 16 ug/ml) ( B
Evidence 4 Activity

Activity

MIC
Antibacterial
8 µg/mL

Target

Candida albicans ATCC 10231

Source & Reference

dbAMP DRAMP

Other

, P. aeruginosa ATCC 9027 (MIC 0.5 ug/ml), S. aureus ATCC 33591 or MRSA (MIC 2 ug/ml) and C. albicans ATCC 10231 (MIC 8 ug/ml). It also inhibit B. anthracis (MIC 16 ug/ml) ( Blower et al., 2018 ). Virus: Active again
Evidence 5 Activity

Activity

MIC
Antibacterial
16 µg/mL

Target

B. anthracis

Source & Reference

dbAMP DRAMP

Other

TCC 33591 or MRSA (MIC 2 ug/ml) and C. albicans ATCC 10231 (MIC 8 ug/ml). It also inhibit B. anthracis (MIC 16 ug/ml) ( Blower et al., 2018 ). Virus: Active against HSV-1, HSV-2 (D>L: D-form is more active)
Evidence 6 Activity

Activity

MIC
Antifungal
0.12 µg/mL

Target

Escherichia coli 004

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
Activity against E. coli 004(MIC 0.12 ug/ml), VREF 032 (MIC 0.25 ug/ml), P. aeruginosa ATCC 9027 (MIC 0.5 ug/ml), S. aureus ATCC 33591
Evidence 7 Activity

Activity

MIC
Antifungal
0.5 µg/mL

Target

Pseudomonas aeruginosa ATCC 9027

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Activity against E. coli 004(MIC 0.12 ug/ml), VREF 032 (MIC 0.25 ug/ml), P. aeruginosa ATCC 9027 (MIC 0.5 ug/ml), S. aureus ATCC 33591 or MRSA (MIC 2 ug/ml) and C. albicans ATCC 10231 (MIC 8 ug/ml). It
Evidence 8 Activity

Activity

MIC
Antifungal
2 µg/mL

Target

Staphylococcus aureus ATCC 33591 or MRSA

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

004(MIC 0.12 ug/ml), VREF 032 (MIC 0.25 ug/ml), P. aeruginosa ATCC 9027 (MIC 0.5 ug/ml), S. aureus ATCC 33591 or MRSA (MIC 2 ug/ml) and C. albicans ATCC 10231 (MIC 8 ug/ml). It also inhibit B. anthracis (MIC 16 ug/ml) ( B
Evidence 9 Activity

Activity

MIC
Antifungal
8 µg/mL

Target

Candida albicans ATCC 10231

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

, P. aeruginosa ATCC 9027 (MIC 0.5 ug/ml), S. aureus ATCC 33591 or MRSA (MIC 2 ug/ml) and C. albicans ATCC 10231 (MIC 8 ug/ml). It also inhibit B. anthracis (MIC 16 ug/ml) ( Blower et al., 2018 ). Virus: Active again
Evidence 10 Activity

Activity

MIC
Antifungal
16 µg/mL

Target

B. anthracis

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

TCC 33591 or MRSA (MIC 2 ug/ml) and C. albicans ATCC 10231 (MIC 8 ug/ml). It also inhibit B. anthracis (MIC 16 ug/ml) ( Blower et al., 2018 ). Virus: Active against HSV-1, HSV-2 (D>L: D-form is more active)
Evidence 11 Activity

Activity

MIC
Antiparasitic
0.12 µg/mL

Target

Escherichia coli 004

Source & Reference

dbAMP 3.0 DRAMP

Other

Source Activity Label Source Definition
Antiparasitic
DRAMP antiparasitic activity supported by activity records against parasitic targets. dbAMP 3.0 classified under the Anti-parasitic function class.
Activity against E. coli 004(MIC 0.12 ug/ml), VREF 032 (MIC 0.25 ug/ml), P. aeruginosa ATCC 9027 (MIC 0.5 ug/ml), S. aureus ATCC 33591
Evidence 12 Activity

Activity

MIC
Antiparasitic
0.5 µg/mL

Target

Pseudomonas aeruginosa ATCC 9027

Source & Reference

dbAMP 3.0 DRAMP

Other

Activity against E. coli 004(MIC 0.12 ug/ml), VREF 032 (MIC 0.25 ug/ml), P. aeruginosa ATCC 9027 (MIC 0.5 ug/ml), S. aureus ATCC 33591 or MRSA (MIC 2 ug/ml) and C. albicans ATCC 10231 (MIC 8 ug/ml). It
Evidence 13 Activity

Activity

MIC
Antiparasitic
2 µg/mL

Target

Staphylococcus aureus ATCC 33591 or MRSA

Source & Reference

dbAMP 3.0 DRAMP

Other

004(MIC 0.12 ug/ml), VREF 032 (MIC 0.25 ug/ml), P. aeruginosa ATCC 9027 (MIC 0.5 ug/ml), S. aureus ATCC 33591 or MRSA (MIC 2 ug/ml) and C. albicans ATCC 10231 (MIC 8 ug/ml). It also inhibit B. anthracis (MIC 16 ug/ml) ( B
Evidence 14 Activity

Activity

MIC
Antiparasitic
8 µg/mL

Target

Candida albicans ATCC 10231

Source & Reference

dbAMP 3.0 DRAMP

Other

, P. aeruginosa ATCC 9027 (MIC 0.5 ug/ml), S. aureus ATCC 33591 or MRSA (MIC 2 ug/ml) and C. albicans ATCC 10231 (MIC 8 ug/ml). It also inhibit B. anthracis (MIC 16 ug/ml) ( Blower et al., 2018 ). Virus: Active again
Evidence 15 Activity

Activity

MIC
Antiparasitic
16 µg/mL

Target

B. anthracis

Source & Reference

dbAMP 3.0 DRAMP

Other

TCC 33591 or MRSA (MIC 2 ug/ml) and C. albicans ATCC 10231 (MIC 8 ug/ml). It also inhibit B. anthracis (MIC 16 ug/ml) ( Blower et al., 2018 ). Virus: Active against HSV-1, HSV-2 (D>L: D-form is more active)
Evidence 16 Activity

Activity

MIC
Antiviral
0.12 µg/mL

Target

Escherichia coli 004

Source & Reference

dbAMP 3.0 DRAMP

Other

Source Activity Label Source Definition
Antiviral
DRAMP antiviral activity supported by activity records against viral targets. dbAMP 3.0 classified under the Anti-viral function class.
Activity against E. coli 004(MIC 0.12 ug/ml), VREF 032 (MIC 0.25 ug/ml), P. aeruginosa ATCC 9027 (MIC 0.5 ug/ml), S. aureus ATCC 33591
Evidence 17 Activity

Activity

MIC
Antiviral
0.5 µg/mL

Target

Pseudomonas aeruginosa ATCC 9027

Source & Reference

dbAMP 3.0 DRAMP

Other

Activity against E. coli 004(MIC 0.12 ug/ml), VREF 032 (MIC 0.25 ug/ml), P. aeruginosa ATCC 9027 (MIC 0.5 ug/ml), S. aureus ATCC 33591 or MRSA (MIC 2 ug/ml) and C. albicans ATCC 10231 (MIC 8 ug/ml). It
Evidence 18 Activity

Activity

MIC
Antiviral
2 µg/mL

Target

Staphylococcus aureus ATCC 33591 or MRSA

Source & Reference

dbAMP 3.0 DRAMP

Other

004(MIC 0.12 ug/ml), VREF 032 (MIC 0.25 ug/ml), P. aeruginosa ATCC 9027 (MIC 0.5 ug/ml), S. aureus ATCC 33591 or MRSA (MIC 2 ug/ml) and C. albicans ATCC 10231 (MIC 8 ug/ml). It also inhibit B. anthracis (MIC 16 ug/ml) ( B
Evidence 19 Activity

Activity

MIC
Antiviral
8 µg/mL

Target

Candida albicans ATCC 10231

Source & Reference

dbAMP 3.0 DRAMP

Other

, P. aeruginosa ATCC 9027 (MIC 0.5 ug/ml), S. aureus ATCC 33591 or MRSA (MIC 2 ug/ml) and C. albicans ATCC 10231 (MIC 8 ug/ml). It also inhibit B. anthracis (MIC 16 ug/ml) ( Blower et al., 2018 ). Virus: Active again
Evidence 20 Activity

Activity

MIC
Antiviral
16 µg/mL

Target

B. anthracis

Source & Reference

dbAMP 3.0 DRAMP

Other

TCC 33591 or MRSA (MIC 2 ug/ml) and C. albicans ATCC 10231 (MIC 8 ug/ml). It also inhibit B. anthracis (MIC 16 ug/ml) ( Blower et al., 2018 ). Virus: Active against HSV-1, HSV-2 (D>L: D-form is more active)
Evidence 21 Activity

Activity

Cell-penetrating Peptides

Target

Hpdls, Mms, Scc-1, Gmsc, Agk And Obc Cells

Source & Reference

CPPsite3.0
CPPsite3

Other

Source Activity Label Source Definition
Cell-penetrating Peptides
CPPsite3.0 experimentally validated cell-penetrating peptide annotation.
Natural residues Linear L Cationic
Protein derived
GFP protein
Periphery And Cytosol
GFP-PG1 is the most efficient tag in penetrating all tested human cells (GFP uptake in GMSC is 30-fold higher than CTB, 17-fold higher than PTD and 48-fold higher than RC101)
In vitro
CCCBCSSSCSSBCCSSCC
Evidence 22 Activity

Activity

50% Hemolysis
Toxicity
80 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 80 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Driving engineering of novel antimicrobial peptides from simulations of peptide-micelle interactions | Biochim Biophys Acta | 2006
Evidence 23 Activity

Activity

50% Cell death
Toxicity
25-50 µg/mL
Cytotoxic
50% Cell death | 25-50 | µg/mL | target cell: Human epithelial cells

Target

Human epithelial cells

Source & Reference

NA
DBAASP
Driving engineering of novel antimicrobial peptides from simulations of peptide-micelle interactions | Biochim Biophys Acta | 2006
Evidence 24 Activity

Activity

40% Cell death
Toxicity
100 µg/mL
Cytotoxic
40% Cell death | 100 | µg/mL | target cell: Intestinal Porcine Epithelial Cells IPEC-J2

Target

Intestinal Porcine Epithelial Cells IPEC-J2

Source & Reference

NA
DBAASP
The Addition of a Synthetic LPS-Targeting Domain Improves Serum Stability While Maintaining Antimicrobial, Antibiofilm, and Cell Stimulating Properties of an Antimicrobial Peptide. | Biomolecules | 2020
Evidence 25 Activity

Activity

70% Hemolysis
Toxicity
80 µg/mL
Hemolytic Cytotoxic
70% Hemolysis | 80 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Evaluation of the inactivation of infectious Herpes simplex virus by host-defense peptides. | Eur J Clin Microbiol Infect Dis | 2000
Evidence 26 Activity

Activity

10% Hemolysis
Toxicity
2 µM
Hemolytic Cytotoxic
10% Hemolysis | 2 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Antimicrobial potency and selectivity of simplified symmetric-end peptides. | Biomaterials | 2014
Evidence 27 Activity

Activity

50% Cell death
Toxicity
10±0.1 µM
Cytotoxic
50% Cell death | 10±0.1 | µM | target cell: Human PBMC

Target

Human PBMC

Source & Reference

NA
DBAASP
Comparison of Cytotoxic Activity in Leukemic Lineages Reveals Important Features of ?-Hairpin Antimicrobial Peptides. | J Cell Biochem | 2017
Evidence 28 Activity

Activity

48% Hemolysis
Toxicity
128 µM
Hemolytic Cytotoxic
48% Hemolysis | 128 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Bioactivity and Bactericidal Mechanism of Histidine-Rich ?-Hairpin Peptide Against Gram-Negative Bacteria. | Int J Mol Sci | 2019
Evidence 29 Activity

Activity

IC50
Toxicity
353.4±70.5 µM
Cytotoxic
IC50 | 353.4±70.5 | µM | target cell: Mouse retinal cells 661W

Target

Mouse retinal cells 661W

Source & Reference

NA
DBAASP
Protegrin-1 Cytotoxicity Towards Mammalian Cells Positively Correlates With the Magnitude of Conformational Changes of the Unfolded Form Upon Cell Interaction | Sci Rep | 2019
Evidence 30 Activity

Activity

IC50
Toxicity
2760±54.1 µM
Cytotoxic
IC50 | 2760±54.1 | µM | target cell: Mouse fibroblasts NIH 3T3

Target

Mouse fibroblasts NIH 3T3

Source & Reference

NA
DBAASP
Protegrin-1 Cytotoxicity Towards Mammalian Cells Positively Correlates With the Magnitude of Conformational Changes of the Unfolded Form Upon Cell Interaction | Sci Rep | 2019
Evidence 31 Activity

Activity

IC50
Toxicity
590.4±58.2 µM
Cytotoxic
IC50 | 590.4±58.2 | µM | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Protegrin-1 Cytotoxicity Towards Mammalian Cells Positively Correlates With the Magnitude of Conformational Changes of the Unfolded Form Upon Cell Interaction | Sci Rep | 2019
Evidence 32 Activity

Activity

IC50
Toxicity
948.9±64.1 µM
Cytotoxic
IC50 | 948.9±64.1 | µM | target cell: Porcine macrophage cells 3D4/2

Target

Porcine macrophage cells 3D4/2

Source & Reference

NA
DBAASP
Protegrin-1 Cytotoxicity Towards Mammalian Cells Positively Correlates With the Magnitude of Conformational Changes of the Unfolded Form Upon Cell Interaction | Sci Rep | 2019
Evidence 33 Activity

Activity

IC50
Toxicity
391.1±71.3 µM
Cytotoxic
IC50 | 391.1±71.3 | µM | target cell: Human neutrophils

Target

Human neutrophils

Source & Reference

NA
DBAASP
Protegrin-1 Cytotoxicity Towards Mammalian Cells Positively Correlates With the Magnitude of Conformational Changes of the Unfolded Form Upon Cell Interaction | Sci Rep | 2019
Evidence 34 Activity

Activity

47.83 ±6.23% Hemolysis
Toxicity
25 µM
Hemolytic Cytotoxic
47.83 ±6.23% Hemolysis | 25 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Matching amino acids membrane preference profile to improve activity of antimicrobial peptides. | Commun Biol | 2022
Evidence 35 Activity

Activity

56.75 ±6.02% Hemolysis
Toxicity
50 µM
Hemolytic Cytotoxic
56.75 ±6.02% Hemolysis | 50 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Matching amino acids membrane preference profile to improve activity of antimicrobial peptides. | Commun Biol | 2022
Evidence 36 Activity

Activity

71.66 ±12.24% Hemolysis
Toxicity
100 µM
Hemolytic Cytotoxic
71.66 ±12.24% Hemolysis | 100 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Matching amino acids membrane preference profile to improve activity of antimicrobial peptides. | Commun Biol | 2022
Evidence 37 Activity

Activity

50% Hemolysis
Toxicity
136.6 µM
Hemolytic Cytotoxic
50% Hemolysis | 136.6 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Membranolytic selectivity of cystine-stabilized cyclic protegrins. | Eur J Biochem | 2000
Evidence 38 Activity

Activity

5% Hemolysis
Toxicity
2 µM
Hemolytic Cytotoxic
5% Hemolysis | 2 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Short Symmetric-End Antimicrobial Peptides Centered on ?-Turn Amino Acids Unit Improve Selectivity and Stability. | Front Microbiol | 2018
Evidence 39 Activity

Activity

1% Hemolysis
Toxicity
<6.3 µM
Hemolytic Cytotoxic
1% Hemolysis | <6.3 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Characterisation and evaluation of synthetic antimicrobial peptides against Bacillus globigii, Bacillus anthracis and Burkholderia thailandensis. | Int J Antimicrob Agents | 2010
Evidence 40 Activity

Activity

IC50
Toxicity
353.4
Cytotoxic
Cytotoxicity: [Ref.31399625] Cytotoxicity: 661W cells(IC50=353.4±70.5µM), HEK293T cells(IC50=2760±54.1µM), NIH-3T3 cells(IC50=719.2±59.5µM), SH-SY5Y cells(IC50=590.4±58.2µM), PMN cells(IC50=948.9±64.1µM), and 3D4/2 cells(IC50=391.1±71.3µM)

Source & Reference

NA
DRAMP
Chem Pharm Bull (Tokyo). 1995 May 43(5):853-858.
Evidence 41 Hemolysis

Source & Reference

APD_complete HemoPI PD_Hemolysis
APD_complete PD_Hemolysis

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation.
Additional Detail Fields 1 fields
CCCBCSSSCSSBCCSSCC